| pubmed-article:8880221 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8880221 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:8880221 | lifeskim:mentions | umls-concept:C0037993 | lld:lifeskim |
| pubmed-article:8880221 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:8880221 | lifeskim:mentions | umls-concept:C0128561 | lld:lifeskim |
| pubmed-article:8880221 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:8880221 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8880221 | pubmed:dateCreated | 1997-3-14 | lld:pubmed |
| pubmed-article:8880221 | pubmed:abstractText | Mirfentanil [N-(2-pyrazinyl)-N-(1-phenethyl-4-piperidinyl)-2-furamide] was studied for its antinociceptive and immunomodulatory effects in mice Mirfentanil (1.0-32.0 mg/kg) increased tail-flick latency to a thermal stimulus and this effect was antagonized (94 +/- 2%) by naltrexone (10.0 mg/kg). Unlike naltrexone, the delta opioid selective antagonist naltrindole (20.0 mg/kg) had no effect on mirfentanil-induced analgesia. In a dose-dependent fashion, the mu-selective antagonists beta-funaltrexamine (1.0-40.0 mg/kg) and naloxonazine (1.0-35.0 mg/kg) blocked mirfentanil (10.0 mg/kg)-induced analgesia up to 75% of the maximum analgesic effect. Norbinaltorphimine (10.0 mg/kg) partially blocked (35%) the maximum analgesic effect following mirfentanil (10.0 mg/kg) administration. Single doses of mirfentanil (0.1-32.0 mg/kg) had no effect on splenic NK activity. However, preadministration of mirfentanil (1.0-10.0 mg/kg) blocked morphine-induced suppression of splenic NK activity. Collectively, the results suggest that mirfentanil is a novel opioid that induces antinociception predominately through mu opioid receptors but, unlike morphine or fentanyl, does not suppress splenic NK activity. | lld:pubmed |
| pubmed-article:8880221 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8880221 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8880221 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8880221 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8880221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8880221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8880221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8880221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8880221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8880221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8880221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8880221 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8880221 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8880221 | pubmed:issn | 0162-3109 | lld:pubmed |
| pubmed-article:8880221 | pubmed:author | pubmed-author:ScottMM | lld:pubmed |
| pubmed-article:8880221 | pubmed:author | pubmed-author:FranceC PCP | lld:pubmed |
| pubmed-article:8880221 | pubmed:author | pubmed-author:BagleyJ RJR | lld:pubmed |
| pubmed-article:8880221 | pubmed:author | pubmed-author:CarrD JDJ | lld:pubmed |
| pubmed-article:8880221 | pubmed:author | pubmed-author:BrockunierL... | lld:pubmed |
| pubmed-article:8880221 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8880221 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:8880221 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8880221 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8880221 | pubmed:pagination | 9-16 | lld:pubmed |
| pubmed-article:8880221 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:meshHeading | pubmed-meshheading:8880221-... | lld:pubmed |
| pubmed-article:8880221 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8880221 | pubmed:articleTitle | Mirfentanil antagonizes morphine-induced suppression of splenic NK activity in mice. | lld:pubmed |
| pubmed-article:8880221 | pubmed:affiliation | Department of Microbiology, Immunology, Parasitology, Louisiana State University Medical Center, New Orleans 70112-1393, USA. dcarr@pop3.lsumc.edu | lld:pubmed |
| pubmed-article:8880221 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8880221 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8880221 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
